کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2998321 | 1180233 | 2016 | 8 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
A Refractory Celiac Patient Successfully Treated With Mesenchymal Stem Cell Infusions
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ATAantiendomysial antibodyRCDIL-15RαUCDMSCEMAAEAIELTCDEosinophils - ائوزینوفیلهاimmunoglobulin - ایمونوگلوبولینinterleukin - اینترلوکینbasophils - بازوفیل هاCeliac disease - بیماری سلیاکRefractory celiac disease - بیماری سلیاک یخ زدهSerum sodium - سرم سدیمMesenchymal stem cell - سلول های بنیادی مزانشیمیIntraepithelial lymphocyte - لنفوسیت داخل اپیتلیالLymphocytes - لنفوسیت هاMonocytes - مونوسیتهاNeutrophils - نوتروفیل هاSerum potassium - پتاسیم سرمhealthy control - کنترل سالم
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Type II refractory celiac disease (RCD), as defined according to the amount of aberrant intraepithelial lymphocytes, is a condition characterized by severe malabsorption syndrome and poor prognosis, with no effective treatment. Based on the regenerative and immunomodulatory properties of mesenchymal stem cells (MSCs), we investigated the feasibility, safety, and efficacy of serial infusions of autologous bone marrow-derived MSCs in a 51-year-old woman with type II RCD. Mesenchymal stem cells were isolated, expanded, and characterized following standard protocols. Monitoring of the patient's malabsorption indexes, mucosal architecture, and percentage of aberrant intraepithelial lymphocytes was scheduled for the time of enrollment, at each infusion, and after 6 months. Determination of mucosal expression of interleukin (IL)-15 and its receptor was also performed. Expansion of MSCs was feasible, and the patient underwent 4 systemic infusions of 2Â Ã 106 MSCs/kg body weight 4 months apart, without adverse effects. During the treatment period, she experienced gradual and durable amelioration of her general condition, with normalization of stool frequency, body mass index, laboratory test results, and mucosal architecture. Remarkably, the expression of IL-15 and its receptor almost completely disappeared. Thus, treatment of RCD with serial MSC infusions seems promising, leading to recovery from the life-threatening condition while blocking the IL-15 pathogenic pathway.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mayo Clinic Proceedings - Volume 91, Issue 6, June 2016, Pages 812-819
Journal: Mayo Clinic Proceedings - Volume 91, Issue 6, June 2016, Pages 812-819
نویسندگان
Rachele MD, Alessandra MD, Maria A. PhD, Elena BSc, Cristina MSc, Alessandro MD, Chiara MSc, Federico MD, Rita PhD, Gino R. MD,